TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23283585
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1.0 Gy
Study: 10866886
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg morphine (M1)
Study: 10866886
Drug: 0.14 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.14 mg/kg morphine (M2)
Study: 10866886
Drug: 0.14 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.14 mg/kg oxycodone (O)
Study: 9083824
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient treatment (INT)
Study: 16231341
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy (IND)
Study: 9083824
Drug: Individual plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual plus group therapy (IND-GRP)
Study: 8212201
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (no prophylactic ALG)
Study: 8212201
Drug: Immediate CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate CsA group (triple therapy)
Study: 3544690
Drug: Bendroflumethiazide 2.5‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 2.5‐5 mg/day
Study: 3544690
Drug: Propranolol 160‐320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160‐320 mg daily
Study: 29398422
Drug: Current users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current users of hormone replacement therapy
Study: 29398422
Drug: Never-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Never-users of hormone replacement therapy
Study: 9565436
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A supplements
Study: 23633748
Drug: Baseline (drug-free)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (drug-free) nights
Study: 17100860
Drug: Interactive educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive educational programme for peer review groups focusing on treatment of chronic heart failure (CHF)
Study: 17100860
Drug: Interactive educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive educational programme for peer review groups focusing on hypertension treatment in diabetes mellitus type 2 (T2DM)
Study: 14675803
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU) with social support from a best friend
Study: 14675803
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU) without social support
Study: 3839424
Drug: Sequential non-cross
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential non-cross resistant combinations (CMFP-AV) at full dose
Study: 18072822
Drug: HEP-40 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP-40 2,400 mg once daily
Study: 18072822
Drug: HEP-40 400
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP-40 400 mg three times daily
Study: 15613421
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (Intrinsa, 150 mug)
Study: 15613421
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (Intrinsa, 300 mug)
Study: 30726946
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary insulin load in patients with obesity
Study: 28320345
Drug: Telephone follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone follow-up at 8, 30, and 60 days after treatment for attempted suicide
Study: 19300199
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued steroids)
Study: 15156427
Drug: Directly Administered
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Administered Antiretroviral Therapy (DAART) program, 1 of 2 daily HAART doses, 5 days per week for 6 months
Study: 8001212
Drug: Omeprazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (two doses)
Study: 2123152
Drug: rt-PA (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (0.6 mg/kg, 2-minute infusion)
Study: 363702
Drug: Fixed standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed standard dosage (20 mg/day)
Study: 31447409
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg teriparatide + denosumab 60 mg every 6 months
Study: 31447409
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg teriparatide + denosumab 60 mg every 6 months
Study: 21325465
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg phytoestrogens
Study: 21325465
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg phytoestrogens
Study: 19264792
Drug: CoPAT (Outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoPAT (Outpatient parenteral antimicrobial therapy)
Study: 19264792
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (semi‐synthetic penicillin or vancomycin with initial low‐dose gentamicin)
Study: 1968319
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dipotassium chlorazepate (DC)
Study: 6992913
Drug: Plain catgut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain catgut subcutaneous fat stitch
Study: 29908043
Drug: PF-06741086 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06741086 (30 mg subcutaneously to 440 mg intravenously)
Study: 8726950
Drug: Inhaled glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticosteroids
Study: 1283117
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day finasteride
Study: 2157231
Drug: Gepirone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone 10 mg
Study: 2157231
Drug: Gepirone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone 20 mg
Study: 30913943
Drug: TENS combined
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS combined with traditional physical therapy
Study: 30913943
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy (Control)
Study: 28321022
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg twice-daily)
Study: 28321022
Drug: Clopidogrel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (150 mg once-daily)
Study: 11038410
Drug: 5.5% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5% CHO solution (8 ml (kg body mass (BM))‐1)
Study: 11038410
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (CON trial)
Study: 22081005
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg/day)
Study: 8860111
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg, three times a day for 3 days)
Study: 31445316
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (olive oil capsules)
Study: 24939630
Drug: Trans-cervical double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-cervical double balloon catheter with extra-amniotic saline infusion (EASI)
Study: 24939630
Drug: Trans-cervical double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-cervical double balloon catheter without extra-amniotic saline infusion (Control)
Study: 15305887
Drug: glimepiride 1-6
Normalized name: glimepiride 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 1-6 mg daily
Study: 31322915
Drug: Pelvic side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic side wall boost (dose not specified)
Study: 29231608
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia combined with EA pretreatment at Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39), Tianshu (ST 25) and Zhongwan (CV 12)
Study: 29231608
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia combined with EA pretreatment at Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39)
Study: 18279411
Drug: Continuous physiotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous physiotherapy (once or twice a week for a total of 30 weeks)
Study: 16413647
Drug: New treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatments for OCD
Study: 10591286
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ecopipam
Study: 10591286
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ecopipam
Study: 10591286
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ecopipam
Study: 6462734
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose nitrofurantoin
Study: 22691567
Drug: Citicoline (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1000 mg every 12 h intravenously during the first 3 days and orally thereafter for a total of 6 weeks [2×500 mg oral tablets given every 12 h])
Study: 2254558
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amiodarone, 200 mg/day (Group 2, n = 98)
Study: 2254558
Drug: Individually treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually treated antiarrhythmic therapy (Group 1, n = 100)
Study: 2254558
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic therapy (Group 3 [control group], n = 114)
Study: 6994772
Drug: guanfacine 2
Normalized name: guanfacine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanfacine 2 mg daily
Study: 1817051
Drug: placebo preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo preparation
Study: 31610073
Drug: Telehealth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth treatment (after all parents received it)
Study: 31610073
Drug: Telehealth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth treatment (for children who entered treatment above target)
Study: 1693055
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of vancomycin (1.0 g)
Study: 1693055
Drug: 2-hour infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-hour infusion of vancomycin (1.0 g)
Study: 6112564
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and Atenolol combined
Study: 24556154
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration after overnight smoking deprivation
Study: 23158941
Drug: Qigong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qigong intervention (specific exercises developed by the Heidelberg School of Chinese Medicine)
Study: 19825948
Drug: Lapatinib 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 175 to 1,800 mg once daily
Study: 19825948
Drug: Lapatinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 500 to 900 mg twice daily
Study: 9454525
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg/d
Study: 15617954
Drug: Troglitazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 600 mg/d
Study: 11782871
Drug: Troglitazone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (both doses)
Study: 2648911
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of daily chemotherapy with streptomycin, isoniazid, rifampin, and pyrazinamide
Study: 2648911
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of chemotherapy (3 times a week)
Study: 2648911
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of daily chemotherapy with streptomycin, isoniazid, rifampin, and pyrazinamide
Study: 24279284
Drug: Structured diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured diabetes education plus insulin therapy
Study: 24279284
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus insulin therapy
Study: 22577038
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg, administered 3 times daily for 3 days
Study: 22577038
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg, administered 3 times daily for 3 days
Study: 22577038
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered 3 times daily for 3 days
Study: 12601115
Drug: Phenylalanine loading
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine loading test (Phe-L)
Study: 8872499
Drug: IVIG 200
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 200 mg/kg
Study: 8872499
Drug: IVIG 400
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 400 mg/kg
Study: 8872499
Drug: IVIG 600
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 600 mg/kg
Study: 28705172
Drug: Rimonabant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (20 mg od)
Study: 28705172
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg tds)
Study: 28705172
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg tds)
Study: 28705172
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg od)
Study: 16495704
Drug: BALI model
Approvals — FDA: no, EMA: no, PMDA: no
Description: BALI model (4-variable prognostic model including BUN >or=25 mg/dL, Age >or=65 years, LDH >or=300 IU/L, IL‐6 >or=300 pg/mL)
Study: 15297138
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose conformal radiotherapy (CFRT) at 74 Gy
Study: 6409208
Drug: Thiazides (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazides (long-term treatment)
Study: 6409208
Drug: Amiloride (substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (substitution for thiazides in long-term treatment)
Study: 28679772
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of ≥1 CTC/7.5 mL before NT
Study: 28679772
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of ≥2 CTCs/7.5 mL before NT
Study: 28679772
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of ≥2 CTCs/7.5 mL before NT in HER2-positive and triple-negative patients
Study: 19675499
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) (no treatment)
Study: 31305347
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without any treatment
Study: 17368254
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (2 ampules of oxytocin at 10 u/mL/amp added to 1000 mL saline at 40 mU/min)
Study: 15559351
Drug: No oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No oxytocin infusion (control group)
Study: 11698316
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of meloxicam 7.5 mg
Study: 11698316
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration of meloxicam 7.5 mg
Study: 9383806
Drug: GM-CSF (Leucomax,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (Leucomax, 5 micrograms/kg) administered subcutaneously for 10 days after chemotherapy
Study: 8031548
Drug: Hydrochlorothiazide (added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (added if monotherapy was inadequate)
Study: 26289810
Drug: High-intensity intermittent
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity intermittent activities coupled with aerobic training (3 sessions of 60 minutes weekly for 8 weeks)
Study: 18165593
Drug: Nimesulide 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 90 mg orally twice daily
Study: 8472517
Drug: ST-679 at
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-679 at 600 mg/die
Study: 8472517
Drug: ST-679 at
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-679 at 1200 mg/die
Study: 8472517
Drug: ST-679 at
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-679 at 1800 mg/die
Study: 8472517
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg/die)
Study: 18799426
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of naltrexone
Study: 27401364
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg EPA+DHA daily for 52 weeks
Study: 27401364
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg EPA+DHA daily for 52 weeks
Study: 20608252
Drug: Drugs approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs approved based on surrogate endpoint trials
Study: 2185673
Drug: Sublingual captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual captopril 12.5 mg
Study: 2185673
Drug: Sublingual captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual captopril 25 mg
Study: 2185673
Drug: Sublingual captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual captopril (both doses)
Study: 23387416
Drug: IMAAC (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMAAC (600 mg)
Study: 23387416
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (600 mg)
Study: 11793035
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (oral tacrolimus 0.2 mg/kg daily + oral prednisone + oral azathioprine)
Study: 9551778
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets and placebo patch
Study: 7998359
Drug: Padma-28 (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Padma-28 (340 mg dried herbal mixture, 2 tablets twice daily for four months)
Study: 3176957
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion epidural analgesia (EDA) with bupivacaine throughout delivery (group B)
Study: 3176957
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion analgesia in the second stage of labor (group A)
Study: 30180054
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no steroid)
Study: 21138388
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid injection (triamcinolone acetonide)
Study: 16191133
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement plus behavioral treatment
Study: 12826989
Drug: Meprobamate (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meprobamate (2,400 mg)
Study: 12826989
Drug: Butabarbital (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butabarbital (400 mg)
Study: 3516077
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg)
Study: 1670723
Drug: Remission reinforcement
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remission reinforcement therapy (teniposide, cytarabine, high‐dose methotrexate)
Study: 1670723
Drug: Four pairs
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four pairs of drugs rotated weekly or every 6 weeks
Study: 30959514
Drug: GHB (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (50 mg/kg p.o.)
Study: 27128712
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2)) every 14 days for four cycles
Study: 27128712
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2))
Study: 19694630
Drug: Venlafaxine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine monotherapy for 12 weeks
Study: 18022033
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg per day
Study: 10745071
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day gossypol
Study: 10745071
Drug: gossypol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: gossypol treatment